Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor-positive advanced or recurrent endometrial cancer
2016-001848-20Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometrial cancer (EC) comparing Palbociclib + letrozole with Placebo + letrozole (2 arms). Primary endpoint: Progression-free survival. Started May 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2016-001848-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001848-20.